BWX Technologies Inc (BWXT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Revenue: $682 million, up 13% year-over-year.
Adjusted EBITDA: $130 million, up 13% year-over-year.
Adjusted Earnings Per Share (EPS): $0.91, up 20% from $0.76 last year.
Government Operations Revenue Growth: 14% increase.
Government Operations Adjusted EBITDA Margin: 21.1%.
Commercial Operations Revenue: $128 million, up 10% year-over-year.
Commercial Operations Adjusted EBITDA Margin: 10.9%, down 100 basis points.
Free Cash Flow: $17 million for the quarter.
Capital Expenditures: $33 million or 4.9% of sales.
Backlog: $1.3 billion in commercial operations, up 78% year-over-year.
Adjusted Effective Tax Rate: 18.3% for the quarter.
Warning! GuruFocus has detected 3 Warning Signs with BWXT.
Release Date: May 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
BWX Technologies Inc (NYSE:BWXT) reported double-digit year-over-year growth in revenue, adjusted EBITDA, and adjusted earnings per share for the first quarter of 2025.
The company achieved a robust bookings performance, with a commercial operations backlog of $1.3 billion, up 78% year-over-year.
BWXT secured significant contracts, including the management and operations contract for the Department of Energy's Strategic Petroleum Reserve and a sole-source contract for domestic uranium enrichment.
The company is expanding its nuclear services portfolio through the pending acquisition of Connectrix and increasing capacity at its Cambridge manufacturing plant.
BWXT's medical segment experienced double-digit revenue and adjusted EBITDA growth, driven by its pet diagnostic product lines, and remains on track for over 20% full-year revenue growth.
BWXT faced negative EACs (Estimate at Completion) of about $11 million, impacting both government and commercial operations.
The company experienced heightened inflation for specialized raw materials in its Candu fuel business line, affecting margins in the first half of the year.
There is uncertainty around the ANPI program, with unclear funding and potential outcomes, despite BWXT being selected as an eligible supplier.
The zirconium cost impact due to geopolitical factors and tariffs poses a challenge, although BWXT has mechanisms to manage this risk.
The timeline for FDA approval of BWXT's moly product remains uncertain, with potential delays into early 2026, affecting the company's entry into contracted sales.
Q: Robb, it looks like there were some negative EACs this quarter of about $11 million based on what's in the 10-Q. Were those EACs all at government operations? Can you share in more detail what the offsets were that allowed the segment to deliver strong margins despite that headwind? A: Robb LeMasters, CFO: No, it wasn't all in government operations. It's about half and half between the commercial and the government business. The commercial operations were impacted by zirconium costs in the fuel business, which we will start to recover in the second half and into 2026. The government operations had various smaller impacts with no significant positive offsets.
Q: Rex, in terms of the recent funds appropriated to support the shipbuilding industry, do you see BWXT as in line to get any of that funding? A: Rex Geveden, CEO: Not much for us in the continuing resolution. However, the reconciliation bill is interesting with potential funding for domestic defense enrichment and DoD nuclear reactors, which could be beneficial for us.
Q: Rex, can you elaborate on the reconciliation package and its potential impact on BWXT, particularly regarding NASA and shipbuilding? A: Rex Geveden, CEO: The reconciliation bill includes funding for accelerating defense enrichment and DoD reactors, which is promising for us. The shipbuilding office setup is positive, emphasizing nuclear shipbuilding. Regarding NASA, there's interest in nuclear thermal propulsion, which aligns with our capabilities.
Q: Robb, regarding the raw material issue at commercial operations, will the second quarter still be your highest margin quarter despite the impact? A: Robb LeMasters, CFO: The second quarter will not have the typical high margins due to the zirconium issue and other mix items. However, we expect margins to pick up in the second half with a better schedule of projects.
Q: Rex, you mentioned perfecting the process on moly. Can you provide an update on the timeline for approval and contracting for 2026? A: Rex Geveden, CEO: We hope for approval in 2025, but it could extend into early 2026. We didn't forecast sales for 2025, but we might enter the spot market. We're addressing technical items from the FDA application and are nearing the finish line.
Q: Can you discuss the enrichment contract and the LEU market for US reactor owners? A: Rex Geveden, CEO: We're in the conceptual stage for a pilot plant with NNSA. The LEU market requires unobligated materials, and the program could evolve with commercial sources or NNSA building the capability. It's too early to determine the exact path.
Q: Robb, is there any reason to think free cash flow seasonality this year is markedly different than previous years? A: Robb LeMasters, CFO: No, we expect a typical pattern with CapEx building over the year and the fourth quarter being the most significant for free cash flow.
Q: Rex, regarding the ANPI program, what are the expected revenues and cadence? A: Rex Geveden, CEO: The ANPI program is uncertain with eight participants, including us. We're negotiating OTAs, but funding and potential are unclear. We're eligible and hope to secure business.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
22 minutes ago
- CNBC
Stock futures are near flat as U.S.-China trade talks continue, May inflation report looms: Live updates
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2025. Brendan Mcdermid | Reuters Stock futures were little changed on Tuesday evening as investors awaited progress on trade policy talks between the U.S. and China. They also anticipated the release of May's consumer inflation report. Futures tied to the S&P 500 slipped 0.07%, while Nasdaq 100 futures pulled back 0.05%. Dow Jones Industrial Average futures lost 28 points, or 0.07%. Trade talks between U.S. and Beijing officials continued for a second day in London on Tuesday. U.S. Treasury Secretary Scott Bessent said he would be departing the ongoing trade talks with China, but U.S. Commerce Secretary Howard Lutnick and U.S. Trade Representative Jamieson Greer would remain to continue the negotiations. Discussions could extend into Wednesday if needed, Lutnick said earlier. The discussions are a key focus for investors and a broader market that remains jittery toward any jolts on trade policy. Both China and the U.S. previously agreed to temporarily pause high tariffs on one another in May, although a fully ironed out agreement has yet to materialize. In regular trading on Tuesday, the S&P 500 rose about 0.6%, posting a third straight positive session. The broad market index sits less than 2% off the high it notched in February. The Nasdaq Composite added 0.6% on Tuesday, while the 30-stock Dow climbed 0.3%. Even as stocks have been resurging, tariff fears and rising bond yields could hang over the market, according to Deutsche Bank. "One key concern is that the Trump administration, buoyed by the market rebound, may resume aggressive tariff rhetoric—potentially triggering renewed retaliation from China and Europe, as seen earlier this year," the firm's group chief economist David Folkerts-Landau said in a Tuesday note. "At the same time, rising long-end bond yields are amplifying fiscal concerns globally, particularly given plans for expanded deficits across multiple major economies," he added. "With several countries already on unsustainable debt paths, the events of 2025 may have accelerated an inevitable reckoning." Investors will get further insight into the U.S. economy on Wednesday morning as the Bureau of Labor Statistics rolls out May's reading of the consumer price index. Economists polled by Dow Jones call for a 0.2% month-over-month increase, while headline CPI is anticipated to have grown 2.4% from 12 months earlier. A hot report could spook investors who are already on edge over inflationary pressures. "Ultimately this report is not expected to cause any significant changes to the Fed's current wait and see approach when it comes to setting rates," said Sam Millette, director of fixed income at Commonwealth Financial Network. "With that being said, we'll have to wait and see if the report shows the anticipated modest rise in price pressure that's expected or if there are any surprises in store for investors." On the earnings front Wednesday, traders will look for reports from Chewy and Oracle .
Yahoo
27 minutes ago
- Yahoo
Byline Bancorp, Inc. Announces Commencement of Secondary Public Offering of Common Stock and Concurrent Share Repurchase
CHICAGO, June 10, 2025--(BUSINESS WIRE)--Byline Bancorp, Inc. ("Byline" or the "Company") (NYSE: BY) announced today that the Estate of Daniel L. Goodwin (the "Estate") and Equity Shares Investors, LLC, an affiliate of the Estate, the selling stockholders of the Company (the "Selling Stockholders"), are offering for sale to the public a total of 4,282,210 shares (the "Offered Shares") of the Company's common stock (the "Secondary Offering"). The Company is not offering or selling any shares of its common stock in the Secondary Offering and will not receive any proceeds from the sale of its shares of common stock in the Secondary Offering. In addition, the Company intends to purchase from the underwriter between $5 million and $10 million of the shares of common stock in the Secondary Offering (the "Share Repurchase"), at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders. The Company intends to execute the Share Repurchase as part of its existing share repurchase program authorized on January 1, 2025. The underwriter will not receive any discount or commission in respect of the shares of common stock being purchased by the Company in the Share Repurchase. The Share Repurchase is conditioned upon the completion of the Secondary Offering, as well as the satisfaction of customary closing conditions, and is expected to close concurrently with the completion of the Secondary Offering. Certain of the Company's directors have indicated an interest in purchasing up to an aggregate $3.1 million in shares of common stock in the Secondary Offering at the public offering price and on the same terms as the other purchasers in the Secondary Offering. J.P. Morgan is serving as the sole underwriter for the Secondary Offering. An automatically effective shelf registration statement on Form S-3 relating to the shares of the Company's common stock subject to the Secondary Offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and is available on the SEC's website at The Secondary Offering will be made only by means of a prospectus supplement and accompanying prospectus that forms a part of the registration statement, copies of which may be obtained, when available, by request from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@ and postsalemanualrequests@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. About Byline Bancorp, Inc. Headquartered in Chicago, Byline Bancorp, Inc. is the parent company of Byline Bank, a full service commercial bank serving small- and medium-sized businesses, financial sponsors, and consumers. Byline Bank has approximately $9.6 billion in assets and operates 46 branch locations throughout the Chicago and Milwaukee metropolitan areas. Byline Bank offers a broad range of commercial and community banking products and services including small ticket equipment leasing solutions and is one of the top Small Business Administration lenders in the United States. Forward-Looking Statements This press release may contain "forward-looking statements" including statements concerning the size and terms of the Secondary Offering and the size and terms of the Share Repurchase. All statements other than statements of historical facts contained in this press release may be forward-looking statements. In some cases, you can identify the forward-looking statements by the use of words such as "may," "could," "should," "would," "expect," "plan," "anticipate," "intend," "forecast," "believe," "estimate," "predict," "propose," "potential," "continue," "scheduled," or the negative of these terms or other comparable terminology. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to those set forth in the periodic reports Byline files with the SEC and those described in the registration statement and the prospectus supplement and accompanying prospectus related to the Secondary Offering. All forward-looking statements included in this press release are made only as of the date of this press release. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, we cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. We expressly disclaim any obligation to update or revise any forward-looking statements, whether because of future events, new information, a change in our views or expectations, or otherwise. We make no prediction or statement about the performance of our common stock. View source version on Contacts Contact For Byline Bancorp, Inc.: Investors / Media: Brooks O. RennieHead of Investor RelationsByline Bank(312) 660-5805brennie@
Yahoo
32 minutes ago
- Yahoo
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem'), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. ('RayzeBio'), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with 225Ac-OncoACP3 are ongoing. Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: 'We are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.' Ben Hickey, President, RayzeBio commented: 'This collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.' Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3. The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025. For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel. About Philogen group Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. FOR MORE INFORMATION Philogen - Investor Relations IR@ - Emanuele Puca | Investor RelationsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
